1 Health Services Research and Development, VA Puget Sound Health Care System, Seattle, Washington; and.
Am J Respir Crit Care Med. 2014 Mar 15;189(6):634-9. doi: 10.1164/rccm.201308-1541PP.
In October 2014, the U.S. Centers for Medicare and Medicaid Services (CMS) will expand its Hospital Readmission Reduction Program (HRRP) to include chronic obstructive pulmonary disease (COPD). Under the new policy, hospitals with high risk-adjusted, 30-day all-cause unplanned readmission rates after an index hospitalization for a COPD exacerbation will be penalized with reduced reimbursement for the treatment of Medicare beneficiaries. In this perspective, we review the history of the HRRP, including the recent addition of COPD to the policy. We critically assess the use of 30-day all-cause COPD readmissions as an accountability measure, discussing potential benefits and then highlighting the substantial drawbacks and potential unintended consequences of the measure that could adversely affect providers, hospitals, and patients with COPD. We conclude by emphasizing the need to place the 30-day COPD readmission measure in the context of a reconceived model for postdischarge quality and review several frameworks that could help guide this process.
2014 年 10 月,美国医疗保险和医疗补助服务中心(CMS)将扩大其医院再入院率降低计划(HRRP),将慢性阻塞性肺疾病(COPD)纳入其中。根据新政策,对于 COPD 加重指数住院后 30 天内全因非计划再入院风险调整率较高的医院,将对 Medicare 受益人的治疗进行报销扣减。在这篇观点文章中,我们回顾了 HRRP 的历史,包括最近将 COPD 纳入该政策。我们对将 30 天全因 COPD 再入院作为问责措施的使用进行了批判性评估,讨论了潜在的益处,然后强调了该措施的实质性缺点和潜在的意外后果,这可能会对提供者、医院和 COPD 患者产生不利影响。最后,我们强调需要将 30 天 COPD 再入院措施置于重新构想的出院后质量模型背景下,并讨论了几个可能有助于指导这一过程的框架。